Key result
Rotavirus vaccines substantially reduce diarrheal disease and mortality in high-burden countries despite lower efficacy.
Why the study?
Rotavirus vaccine efficacy in low-income settings with high child mortality is lower than in high-income populations, warranting an overview of vaccine efficacy, effectiveness, and impact across settings.
Do oral, live-attenuated rotavirus vaccines reduce diarrheal disease and mortality in children in high-mortality settings?
Do oral, live-attenuated rotavirus vaccines reduce diarrheal disease and mortality in children in high-mortality settings?
Rotavirus vaccines are cost-effective and substantially reduce diarrheal disease and mortality in high-burden countries despite lower efficacy compared to high-income settings.
No takes yet. Share an insight, caveat, or question.
Supports expanded use in high-burden settings; leaves open strategies to close efficacy gaps versus high-income countries.
Varghese et al. (2022) conducted a review in Rotavirus and diarrheal disease. Oral, live-attenuated rotavirus vaccines was evaluated. Rotavirus vaccines substantially reduce diarrheal disease and mortality and are cost-effective in countries with high burden, despite lower efficacy compared to high-income settings.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: